Peter Doran

University College Dublin — Ireland

Medicine · Health Sciences

45h-index5.7kcitations220works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

COVID-19 Clinical Research Studies(29), SARS-CoV-2 and COVID-19 Research(23), Chronic Kidney Disease and Diabetes(15), Long-Term Effects of COVID-19(15), Ethics in Clinical Research(13)

Publications205 total

Development of novel circulating biomarkers for predicting lung function decline in Lymphangioleiomyomatosis
2025
Identification of novel markers of progression in Idiopathic Pulmonary Fibrosis (IPF) and Chronic Hypersensitivity Pneumonitis (CHP)
2025
Public perceptions of participation in trials in the intensive care unit: an ERS Clinical Research Collaboration international cross-sectional survey across 13 countries
2025
Molecular basis for the interactions of eIF2β with eIF5, eIF2B, and 5MP1 and their regulation by CK2
RNA·2025· 1 citedOpen Access
Specific thresholds of circulating antibody titers predict against infection and reduced disease severity in SARS-CoV-2 close contacts
The Journal of Immunology·2025· 1 citedOpen Access
A Novel Composite Serum Protein Biomarker of Lymphangioleiomyomatosis Identified by Machine Learning
American Journal of Respiratory and Critical Care Medicine·2025
Quantifying the carbon footprint of clinical research activities – a scoping review protocol
HRB Open Research·2025Open Access
Predicting Outcomes using DIGital TechnologY in patients with Interstitial Lung Disease (PRODIGY-ILD): Protocol for a Prospective Cohort Study
BMJ Open·2025Open Access
A mathematical model of <i>Clostridioides difficile</i> transmission in long-term care facilities
Mathematical Biosciences & Engineering·2025Open Access
Withdrawn: Comparative efficacy of an antimicrobial liquid bandage and antibiotic aerosol for bovine digital dermatitis treatment.
2024
What is the carbon footprint of academic clinical trials? A study of hotspots in 10 trials
BMJ Open·2024· 10 citedOpen Access
Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection
Frontiers in Immunology·2024· 10 citedOpen Access
Quantifying the carbon footprint of academic clinical trials: building the evidence base and hotspot identification
2024· 2 citedOpen Access
Robust and Persistent B Cell Responses Following Third-Dose SARS-CoV-2 Vaccine Determine Protection from SARS-CoV-2 Infection
SSRN Electronic Journal·2024Open Access
2338. Robust and Persistent B Cell Responses Following Third Dose SARS-CoV-2 Vaccine Determine Protection from COVID-19
Open Forum Infectious Diseases·2023Open Access
2356. Close correlation of RBD with Live Viral Neutralising Capacity Across Variants and Time Supports Use of RBD Thresholds to Predict Protective Host Immunity
Open Forum Infectious Diseases·2023Open Access
Impact of vaccination and variants of concern on long COVID clinical phenotypes
BMC Infectious Diseases·2023· 11 citedOpen Access
Associations between host microbiome and inflammation suggest role for host microbiome in driving COVID-19 disease severity
Microbes and Infection·2023· 6 citedOpen Access
Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time
Nature Communications·2023· 21 citedOpen Access
Establishing severe acute respiratory infection (SARI) surveillance in a sentinel hospital, Ireland, 2021 to 2022
Eurosurveillance·2023· 15 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

David W. Murray(8), Donal J. Buggy(6), Hugh R. Brady(6), Denise M. Sadlier(6), Padraic MacMathúna(6), David J. Murray(5), Eoin J. Cotter(5), Andrea P. Malizia(5), David Lappin(4), Anna Henger(4), Matthias Kretzler(4), P. Ećimović(4), Joseph S. Butler(4), Eileen P. Treacy(4), William G. Powderly(4), David Murray(4), Niamh E. Kieran(3), Susan Connolly(3), Catherine Godson(3), Patrick Murray(3)